Showing results (801-810 of 866) with videos related to
Sort By:
Pageof 87
JCO Clinical Cancer Informatics|April 8, 2026
Childhood Cancer Data Initiative Participant Index: Mapping Pediatric Cancer Data to Facilitate Cross-Study Integrated AnalysisSubhashini Jagu, Jaime M Guidry Auvil, Mark D Cunningham, et al.Nanoscale|July 24, 2024
Correction: Towards control of excitonic coupling in DNA-templated Cy5 aggregates: the principal role of chemical substituent hydrophobicity and steric interactionsSebastián A Díaz, Gissela Pascual, Lance K Patten, et al.International Journal of Environmental Research and Public Health|June 21, 2020
Converging on Bladder Health through Design Thinking: From an Ecology of Influence to a Focused Set of Research QuestionsJessica B Lewis, Sonya S Brady, Siobhan Sutcliffe, et al.Journal of Pediatric and Adolescent Gynecology|October 7, 2024
Bladder Health Knowledge, Attitudes, and Beliefs among US Adolescent WomenDeepa R Camenga, Sonya S Brady, Andrea Bilger, et al.British Journal of Haematology|June 10, 2000
A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular responseJ M Foran, R K Gupta, D Cunningham, et al.European Journal of Cancer (Oxford, England : 1990)|July 12, 2002
Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)E Van Cutsem, M Dicato, J Wils, et al.European Journal of Cancer (Oxford, England : 1990)|March 19, 2018
Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre studyL C Hewitt, I Z Inam, Y Saito, et al.Bioorganic & Medicinal Chemistry Letters|August 7, 2013
Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonistsJohn L Gilmore, James E Sheppeck, Jim Wang, et al.European Journal of Cancer (Oxford, England : 1990)|February 5, 2020
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 studyE Van Cutsem, K Muro, D Cunningham, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2013
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinomaA C Roy, S R Park, D Cunningham, et al.Pageof 87